The Journal of Thoracic and Cardiovascular Surgery
Volume 140, Issue 2 , Pages 346-351 , August 2010

Bosentan induces clinical and hemodynamic improvement in candidates for right-sided heart bypass surgery

  • Keiichi Hirono, MD

      Affiliations

    • Department of Pediatrics, University of Toyama, Japan
    • ,
  • Naoki Yoshimura, MD

      Affiliations

    • First Department of Surgery, University of Toyama, Japan
    • ,
  • Masato Taguchi, PhD

      Affiliations

    • Department of Clinical Pharmacy, University of Toyama, Japan
    • ,
  • Kazuhiro Watanabe, MD

      Affiliations

    • Department of Pediatrics, University of Toyama, Japan
    • ,
  • Tsuneyuki Nakamura, MD

      Affiliations

    • Department of Pediatrics, Kanazawa Medical University, Kanazawa, Japan
    • ,
  • Fukiko Ichida, MD

      Affiliations

    • Department of Pediatrics, University of Toyama, Japan
    • Corresponding Author InformationAddress for reprints: Fukiko Ichida, MD, Department of Pediatrics, Faculty of Medicine, University of Toyama, 2630 Sugitani, Toyama, Toyama, 930–0194 Japan.
    • ,
  • Toshio Miyawaki, MD

      Affiliations

    • Department of Pediatrics, University of Toyama, Japan

Received 2 November 2009 ,Revised 4 February 2010 ,Accepted 21 March 2010.

References 

  1. Galiè N, Torbicki A, Barst R, Dartevelle P, Haworth S, Higenbottam T, et al. Guidelines on diagnosis and treatment of PAH. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J. 2004;25:2243–2278
  2. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896–903
  3. Galiè N, Seeger W, Naeije R, Simonneau G, Rubin LJ. Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43:81–88S
  4. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo–controlled study. Lancet. 2001;358:1119–1123
  5. Gatzoulis MA, Rogers P, Li W, Harries C, Cramer D, Ward S, et al. Safety and tolerability of bosentan in adults with Eisenmenger physiology. Int J Cardiol. 2005;98:147–151
  6. Schulze-Neick I, Gilbert N, Ewert R, Witt C, Gruenig E, Enke B, et al. Adult patients with congenital heart disease and pulmonary hypertension: first open prospective multicenter study of bosentan therapy. Am Heart J. 2005;150:716
  7. Galiè N, Beghetti M, Gatzoulis MA, Granton J, Berger RM, Lauer A, et al. Bosentan therapy in patients with Eisenmenger syndrome. A multicenter, double–blind, randomized, placebo controlled study. Circulation. 2006;114:48–54
  8. Apostolopoulou SC, Papagiannis J, Rammos S. Bosentan induces clinical, exercise and hemodynamic improvement in a pre-transplant patient with plastic bronchitis after Fontan operation. J Heart Lung Transplant. 2005;24:1174–1176
  9. Votava-Smith JK, Perens GS, Alejos JC. Bosentan for increased pulmonary vascular resistance in a patient with single ventricle physiology and a bidirectional Glenn shunt. Pediatr Cardiol. 2007;28:314–316
  10. Connolly D, Rutkowski M, Auslender M, Artman M. The New York University Pediatric Heart Failure Index: a new method of quantifying chronic heart failure severity in children. J Pediatr. 2001;138:644–648
  11. Bridges ND, O'Lauhlin MP, Mullins CE, Freed MD. In:  Allen HD,  Gutgesell HP,  Clark EB,  Driscoll DJ editor. Moss and Adams Heart Disease in Infants, Children, and Adolescents. 6th ed. Cardiac catheterization, angiography, and intervention. Volume 1:Baltimore: Williams & Wilkins; 2001;p. 276–324
  12. Grossman W. Clinical measurement of vascular resistance and assessment of vasodilator drugs. In:  Grossman W editors. Cardiac Catheterization and Angiography. Philadelphia: Lea and Febiger; 1991;p. 143–151
  13. Cloutier A, Ash JM, Smallhorn JF, Williams WG, Trusler GA, Rowe RD, et al. Abnormal distribution of pulmonary blood flow after the Glenn shunt or Fontan procedure: risk of development of arteriovenous fistulae. Circulation. 1985;72:471–479
  14. Alejos JC, Williams RG, Jarmakani JM, Galindo AJ, Isabel-Jones JB, Drinkwater D, et al. Factors influencing survival in patients undergoing the bidirectional Glenn anastomosis. Am J Cardiol. 1995;75:1048–1050
  15. Pridjian AK, Mendelsohn AM, Lupinetti FM, Beekman RH, Dick M, Serwer G, et al. Usefulness of the bidirectional Glenn procedure as a staged reconstruction for the functional single ventricle. Am J Cardiol. 1993;71:959–962
  16. Lutz J, Gorenflo M, Habighorst M, Vogel M, Lange PE, Hocher B. Endothelin-1- and endothelin-receptors in lung biopsies of patients with pulmonary hypertension due to congenital heart disease. Clin Chem Lab Med. 1999;37:423–428
  17. Yoshibayashi M, Nishioka K, Nakao K, Saito Y, Matsumura M, Ueda T, et al. Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects. Evidence for increased production of endothelin in pulmonary circulation. Circulation. 1991;84:2280–2285
  18. Fratz S, Geiger R, Kresse H, Roemer G, Hennig M, Sebening W, et al. Pulmonary blood pressure, not flow, is associated with net endothelin-1 production in the lungs of patients with congenital heart disease and normal pulmonary vascular resistance. J Thorac Cardiovasc Surg. 2003;126:1724–1729
  19. Vincent JA, Ross RD, Kassab J, Hsu JM, Pinsky WW. Relation of elevated plasma endothelin in congenital heart disease to increased pulmonary blood blow. Am J Cardiol. 1993;71:1204–1207
  20. Barst RJ, Ivy D, Dingemanse J, Widlitz A, Schmitt K, Doran A, et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin Pharmacol Ther. 2003;73:372–382
  21. Rosenzweig EB, Ivy DD, Widlitz A, Doran A, Claussen LR, Yung D, et al. Effects of long–term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol. 2005;46:697–704
  22. Maiya S, Hislop AA, Flynn Y, Haworth SG. Response to bosentan in children with pulmonary hypertension. Heart. 2006;92:664–670
  23. Hiramatsu T, Imai Y, Takanashi Y, Seo K, Terada M, Aoki M, et al. Time course of endothelin-1 and adrenomedullin after the Fontan procedure. Ann Thorac Surg. 1999;68:169–172
  24. Sakamoto K, Ikai A, Fujimoto Y, Ota N. Novel surgical approach ‘intrapulmonary-artery septation’ for Fontan candidates with unilateral pulmonary arterial hypoplasia or pulmonary venous obstruction. Interact Cardiovasc Thorac Surg. 2007;6:150–154

 Disclosures: None.

PII: S0022-5223(10)00318-1

doi: 10.1016/j.jtcvs.2010.03.023

The Journal of Thoracic and Cardiovascular Surgery
Volume 140, Issue 2 , Pages 346-351 , August 2010

Article Tools